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OBJECTIVES: Payers in the U.S. are increasingly employing aggressive cost sharing 
strategies for specialty drugs. We conducted a systematic review of the published 
evidence on the associations between patient cost sharing and use of specialty drugs, 
use of non-drug medical services, and health outcomes and spending. METHODS: A 
MEDLINE search for U.S.-based studies published in English between 1995 and 2013 
was conducted using various combinations of terms for cost sharing and specialty 
drugs and/or common conditions for which they are indicated. Additional studies 
were obtained from reference lists of identified studies. Key methodological elements 
of the included studies were extracted and findings were captured to determine 
effects of cost sharing. RESULTS: We identified 15 articles that focused on one or more 
diseases, including MUltiple Sclerosis (n= 8), cancer (n= 7), Rheumatoid Arthritis (n= 5), 
and other conditions (n= 4). Majority of the studies (n= 14) used administrative claims 
data on privately insured patients from the year 2009 or earlier, during which time few 
private insurers were employing aggressive cost sharing for specialty drugs. Outcomes 
included prescription abandonment (n= 2), initiation or any utilization (n= 7), adher-
ence (n= 8), persistence/discontinuation (n= 6), number of claims (n= 1), and drug 
spending (n= 1). Findings generally indicated reductions in specialty drug utilization 
associated with higher cost sharing. However, the evidence was not consistent; the 
magnitude and/or statistical significance of the effects of cost sharing varied by dis-
ease and type of outcome. None of the studies examined the effect of specialty tier 
cost sharing seen under Medicare Part D or health insurance exchanges; or the effect 
of cost sharing on medical utilization, spending, or health outcomes. CONCLUSIONS: 
Evidence till date generally indicates reductions in specialty drug utilization associ-
ated with higher cost sharing, with effects varying by type of disease and specialty 
drug outcome. We draw upon our findings and the gaps in evidence to summarize 
future directions for research and policy.
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OBJECTIVES: The impact of health economics and outcomes research (HEOR) 
evidence on reimbursement decisions in the U.S. is not well understood, yet the 
continued and increasing investment in HEOR by pharmaceutical companies indi-
cates a perceived positive impact. We sought to understand U.S. payers’ prefer-
ences for HEOR evidence when making reimbursement decisions and to assess 
the alignment between payers and pharmaceutical companies with respect to the 
types of HEOR evidence that are important for various product and market sce-
narios. METHODS: We conducted an online, stated choice survey with individuals 
involved in the formulary decision-making process for U.S. payer and pharmacy 
benefit manager (PBM) organizations and those involved in the decision to invest 
in HEOR for pharmaceutical companies. We presented each individual with thirteen 
product profiles and asked them to rate the importance of several types of HEOR 
evidence to support U.S. formulary placement decisions for each profile. We used 
a logistic regression model to assess the product and market attributes that are 
associated with the stated importance of each type of evidence and to compare 
the alignment between respondents from pharmaceutical and payer/PBM organi-
zations. RESULTS: We received 31 responses from payers and 63 responses from 
individuals within pharmaceutical companies. Preliminary results indicate differ-
ences between the two stakeholder groups in the perceived importance of budget 
impact, resource utilization/cost offset, and adherence/compliance evidence. We 
report the most influential factors in the types of HEOR evidence that are stated 
to have an impact on formulary decision-making. CONCLUSIONS: The findings of 
this survey provide us with a better understanding of the specific types of HEOR 
evidence payers are interested in for pharmaceutical products entering the market. 
This nuanced understanding of payer preferences may allow for greater alignment 
between payer organizations and pharmaceutical companies, and will assist phar-
maceutical companies in planning future investments.
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OBJECTIVES: The Californian Technology Assessment Forum (CTAF) publishes 
reports that make recommendations on the comparative clinical effectiveness and 
value of medical interventions. The recommendations of CTAF, which is managed 
by the Institute for Clinical and Economic Review and funded by Blue Shield of 
California, are not binding and they do not determine health plan benefit coverage. 
In April 2014, CTAF gained a degree of public attention when they recommended 
that the Hepatitis C virus (HCV) treatments OLYSIO and SOVALDI be only used 
immediately in patients with advanced liver disease or those awaiting transplants 
based on a report including cost-utility economic modelling. This research aimed 
to systematically analyse all CTAF reports to determine what types of health 
technologies they assess, how restrictive their recommendations are, and how 
this has evolved over time. METHODS: All publically available CTAF reports were 
extracted and their date, indication, technology type, and recommendation were 
extracted. RESULTS: CTAF have issued 119 medical technologies appraisals since 
October 2002. 26/119 (22%) were recommended, 18/119 (15%) received restricted 
recommendations, and 75/119 (63%) not recommended. 33/119 appraisals (28%) 
were for diagnostic tests, 28/119 devices (24%), 27/119 (23%) surgery, 25/117 (21%) 
radio/radiation/laser-based emission therapies, 3/117 (3%) other, and only 3/117 
(3%) branded drugs. The branded drug submissions were for Avastin in metastatic 
OBJECTIVES: Biologic agents represent significant medical advances for rheumatoid 
arthritis (RA), and multiple sclerosis (MS). Yet, specialty tiers under the initial cover-
age limit (ICL) period of Medicare Part D require a coinsurance of up to 33% for such 
drugs. This study is the first to examine the impact of cost-sharing increases faced 
with specialty tiers on adherence and discontinuation among Medicare patients 
using RA and MS biologics. METHODS: This quasi-experimental study examined 
changes in outcomes across the Part D catastrophic coverage period in the previous 
year (pre-period) and the ICL period in the current year (post-period) for patients 
not receiving low-income subsidies (non-LIS) who faced coinsurance levels of 5% in 
the pre-period and 25%-33% in the post-period compared to a control group of LIS 
patients who faced the same cost-sharing ($5 copay) in the pre- and post-periods. 
Using the 2006-2010 5% Medicare files we identified patients with MS (ICD-9-CM 340.
xx) and RA (ICD-9-CM 714.xx) with continuous fee-for-service and Part D coverage 
and use of Part D biologics indicated for MS (N= 1887) and RA (N= 1982), respec-
tively, during the pre-period. Outcomes included adherence (proportion of days 
covered> = 0.8) and discontinuation (continuous 30-day gap) for Part D-covered, Part 
B-covered, and all biologics. GEE logit regressions adjusting for patient demograph-
ics and clinical severity and Part D plan formulary characteristics were estimated. 
Patient-level fixed-effects models were used in sensitivity analyses. RESULTS: 
The substantial increase in cost sharing under specialty tiers was associated with 
lower adherence (MS:OR= 0.56,p< 0.001; RA:OR= 0.50,p< 0.001) and higher likelihood 
of having gaps in Part D biologic (MS:OR= 1.56,p< 0.001; RA:OR= 2.73,p< 0.001) among 
non-LIS compared to LIS patients. Overall biologic use also declined due to limited 
substitution with Part B biologics in non-LIS patients. Sensitivity analyses showed 
consistent findings. CONCLUSIONS: The increased cost sharing under specialty 
tiers was associated with a decline in adherence and increase in discontinuation 
of MS and RA biologics.
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OBJECTIVES: A key portion of the Affordable Care Act’s new coverage, particu-
larly for chronic disease, is the prescription drug benefit. Each plan’s generos-
ity will depend on the particular mix of drugs for a given patient, not just the 
benefit structure. For a market basket of drugs, we assess the generosity of drug 
coverage for the four metal tiers in the Federally Facilitated health insurance 
exchanges. METHODS: We examined the 27 federally facilitated exchanges and 
7 partnership exchanges, for which characteristics of all plans on the exchanges 
were publicly available from data.gov for 2014. These files, however, do not contain 
drug formulary data, so we also use a unique data source of drug formulary data, 
from Managed Markets Insight & Technology. We were able to identify a total 
of 2,826 unique plan-formulary combinations with formulary and price data for 
21 drugs in these therapeutic areas. For each drug, we collected the price for a 
standard prescription fill from drugs.com, which allowed us to convert coinsur-
ance rates into prices. We then created a generosity index as the ratio of the 
out-of-pocket payment to the price of the drug. RESULTS: For individuals with 
higher out-of-pocket spending, there is considerable variation in the generosity 
of prescription drug coverage in all metal tiers. Comparisons by plan type indicate 
that PPO plans provide more generous prescription drug coverage, except in the 
bronze tier, for which HMO plans are significantly more generous than PPO plans 
until individuals have spent $5,000, or more, out of pocket. CONCLUSIONS: Given 
the substantial variation in generosity of drug coverage, consumers may have 
trouble finding the plan that best balances their ability to pay premiums, toler-
ance for financial risk, and preferences between prescription drug and all other 
costs.
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OBJECTIVES: A “biosimilar” is a biological medicine similar to a licensed biologi-
cal medicine (“originator”). As of October 2014, six biosimilars are licensed and 
marketed in Great Britain (GB) (three biosimilar filgrastims, two biosimilar epo-
etins and one biosimilar somatropin). Biological medicines are highly costly to 
the NHS, so it is expected that biosimilars will have an increasing presence as a 
cost-saving mechanism. This study explored the uptake of biosimilars within GB 
formularies. METHODS: Websites of acute trusts in England and health boards in 
Scotland and Wales were searched for the most recent drug formularies. The pres-
ence of biosimilars in a formulary was examined for all six products. Formularies 
that listed at least one biosimilar were considered to have a positive recognition 
of these products. RESULTS: Of 158 acute trusts in England and 21 health boards 
in Scotland and Wales, 176 websites were available, providing 144 formularies 
(England: 127, Scotland: 9; Wales: 7; England/Scotland shared: 1). 17 formular-
ies were shared across trusts and boards. At least one biosimilar was listed in 
63 formularies. While 45 formularies listed at least one biosimilar filgrastim, 31 
and 17 formularies listed biosimilar somatropin and epoetin, respectively. Five 
formularies listed at least one biosimilar from each of the three classes, 20 for-
mularies listed at least one from two classes, and 38 formularies listed at least 
one from only one class. In 19 formularies, at least one biosimilar was listed in 
preference to an originator product as first line therapy (filgrastim: 16; somatro-
pin: 5; epoetin: 1). CONCLUSIONS: The results of this survey suggest that 44% of 
formularies in Great Britain list at least one biosimilar, and in 30% of these, these 
are listed in preference to the originator product. This appears to be a low level 
of penetration into formularies given that these biosimilars have been available 
for over five years.
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tool and disseminated it to a self-selected cohort of 11 small primary care practices 
that had previously achieved PCMH recognition from the NCQA. We assessed the 
cost of transformation between 2008 and 2011 using the tool. The cost of transfor-
mation was divided into four categories: the cost of NCQA patient centered recog-
nition activities, the application cost of obtaining recognition, the cost of changes 
to practice culture, and the cost of external collaborations. Costs were averaged 
and weighted by the number of FTE providers in each practice in order to make 
the results comparable across practices. RESULTS: Three practices completed the 
tool. The weighted average cost of PCMH transformation was $35,508 per FTE pro-
vider in the year before recognition was achieved, and $38,218 in the recognition 
year itself. The most costly patient-centered activity (weighted average) in the pre-
transformation year was “providing self-care support” ($4,863/FTE provider), while 
“measuring and improving performance” ($9,503/FTE provider) was the most costly 
in the transformation year. CONCLUSIONS: The cost of recognition as a PCMH is a 
substantial but not insurmountable barrier to practice transformation. This informa-
tion may be used by payers and policymakers to direct financial resources to primary 
care practices as they transform to the PCMH model. Indirect financial resources 
that assist in collecting cost data may also promote diffusion of the PCMH model.
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OBJECTIVES: Patient-centered outcomes have become increasingly important 
and relevant in making informed healthcare decisions. However, the influence of 
patient’s perspective in economic evaluation studies remains unknown. This study 
sought to systematically review CEA studies conducted from the patient’s perspec-
tive. METHODS: PUBMED, EMBASE, and Cochrane Central database were searched 
through May 2014 for CEA studies that used patient’s perspective. Essential char-
acteristics of these economic studies were extracted and compared. The reporting 
quality of these studies was evaluated using the ISPOR guideline, Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS). RESULTS: A total of 21 out of 
32 studies retrieved met the inclusion criteria. These studies, in average, met 17 of 24 
reporting criteria specified in CHEERS, and were conducted in the US (5), Europe (6), 
Asia (6), and others (4). Among the 21 CEA studies, 9 evaluated pharmacotherapy and 
12 non-drug intervention. Of the 8 studies that mentioned reasons for using patient’s 
perspective, patient’s consideration of financial burden associated with medical inter-
vention was the most common one (7), followed by possible influence on patient 
adherence and utilization of resources (1). Societal (3), government (1), institutional 
(12), or third-party payer (2) perspectives were also used in majority of the studies. 
Direct medical cost generally considered in the studies were out-of-pocket costs such 
as copayment or co-insurance for drugs, office visits, tests, and procedures, whereas 
direct non-medical cost included travel and food cost. Sensitivity analyses were per-
formed in 19 studies, and governmental agencies or university grants were the most 
common funding sources (14) disclosed by17 studies. CONCLUSIONS: Currently, there 
is a paucity of CEA studies conducted from patient’s perspective in the literature, and 
the reporting quality of these studies was not optimal. With the increasing focus of 
patient-centered outcomes in health policy research, use of patient’s perspective in 
economic studies should be advocated.
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OBJECTIVES: In observational studies, identification of the impact of increased cost 
sharing on expenditures is plagued by an individual’s self-selection into copay-
ment and deductible levels based on their health state. The objective of this study 
was to evaluate the effect of increasing patient’s cost sharing on future third party 
expenditures using an instrumental variables (IV) approach to mitigate selection 
bias. METHODS: Data from the Medical Expenditure Panel Survey’s Longitudinal 
Household Component (2011-2012), a nationally representative survey of the U.S. 
civilian non-institutionalized population, was used. Analysis accounted for the 
survey’s clusters, strata, and sampling weights. Respondents were included in the 
study if they were at or above the age of 18 and if they had insurance coverage. We 
evaluated the effect of patient’s out-of-pocket payments on total third party expen-
ditures in the following year, using a limited information maximum likelihood IV 
estimator. The three excluded instruments determining self-selected levels of cost 
sharing were, attitudes toward health insurance; attitudes that might influence 
decisions to use health services; and perceived physical health status. We evalu-
ated the validity of our IV estimation assumptions on instrument relevance and 
exogeneity using several tests. Other covariates adjusted in the models included age, 
sex, race, ethnicity, family size, income, geographic-location, and comorbidities in 
2011. RESULTS: The mean age of the sample was 46 with a majority of female (52%); 
Caucasian (81%); and non-Hispanic (85%). The endogeneity test rejected the null 
hypothesis that there was no self-selection. The IV estimates indicated that an one 
dollar increase in patient’s cost sharing increased future third party expenditures 
by $12.6 (95% CI = 5.7 to 19.4). In contrast, naïve estimates ignoring endogeneity 
displayed a modest increase of $0.6 (95% CI = 0.2 to 1.0). CONCLUSIONS: Health 
policy effect of increasing patient’s cost sharing to reduce health expenditures may 
have an opposite effect and increase future expenditures.
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breast cancer in 2008, for HCV treatments in April 2014, and, for an appraisal of 
new HCV treatments in December 2014. CONCLUSIONS: CTAF have appraised a 
wide range of technologies but have only started appraising pharmaceuticals very 
recently. Gaining CTAF approval is far from a formality with over half of appraisals 
being not recommended. As management of rising healthcare costs continues to 
become an increasing payer challenge, CTAF will likely appraise greater numbers of 
high-cost pharmaceuticals using cost-utility analyses with their recommendations 
potentially becoming increasingly influential.
HealtH care use & PolIcy stuDIes – Health care costs & management
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OBJECTIVES: To characterize differences between Hispanic and non-His-
panic white adults in the United States with regard to healthcare resource 
utilization and costly health conditions. METHODS: Demographics and 
healthcare resource utilization among Hispanic and non-Hispanic white 
adults (≥ 20 years) were compared from a cross-sectional study using de-iden-
tified data from the 2013 National Health Interview Survey. The most costly 
health conditions for each population were identified from the 2010-2011 
Medical Expenditure Panel Survey (MEPS). RESULTS: While sex distribution 
was similar in both cohorts, the Hispanic cohort was generally younger (P< 0.0001; 
50.1% in the 20-39 year range vs 31.3% of non-Hispanic whites), with lower educa-
tion (P< 0.0001) and household income (P< 0.0001), although employment was higher 
(63.5% vs 57.5%; P< 0.0001). Relative to non-Hispanic whites, greater proportions of 
Hispanics reported not having a physician visit in the past year (30.9% vs 16.5%; 
P< 0.0001) and less emergency room use (17.3% vs 18.3%; P= 0.0094). Utilization of 
several preventative resources was significantly lower among Hispanics, including 
flu vaccination (31.9% vs 43.8%; P< 0.0001), pneumonia vaccination (14.0% vs 22.4%; 
P< 0.0001), mammograms among females ≥ 40 years (53.2% vs 56.8%; P= 0.0418), 
and prostate-specific antigen tests among males ≥ 40 years (29.6% vs 44.5%; 
P< 0.0001); however, PAP tests were similar among females (Hispanic 48.4%, white 
50.4%; P= 0.1897), as was colonoscopy among those ≥ 50 years (23% in both groups; 
P= 0.9137). MEPS data showed differences in the most costly conditions. In subjects 
aged ≥ 65 years, the most costly conditions were heart disease in Hispanics and 
diabetes mellitus among non-Hispanic whites. For those < 65 years, the most costly 
conditions in males were trauma-related disorders among Hispanics and heart 
conditions in non-Hispanic whites; births was the most costly condition among 
females in both cohorts. CONCLUSIONS: Hispanics were characterized by lower fre-
quency of physician visits and several preventative/screening healthcare measures, 
suggesting different healthcare cost drivers compared with non-Hispanic whites.
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OBJECTIVES: Since 2011, the Centers for Medicare and Medicaid Services has 
required all long term care facilities to implement a short fill supply for all solid 
oral dosage forms in order to reduce medication wastage from medication discon-
tinuation. The objective of this study was to evaluate potential savings that could be 
achieved from a 15-day initial fill policy for selected out-patient medications in the 
Mississippi Medicaid program. METHODS: A retrospective analysis was conducted 
using Mississippi Medicaid fee-for-service and managed care pharmacy claims data 
for the period January 1, 2013 through December 31, 2013. Oral drugs, costing more 
than $1000 per prescription, were evaluated for inclusion in the 15-day initial fill 
model. All new starts for these medications during the year were identified and ana-
lyzed for persistency and average amount paid. Medications were selected for fur-
ther evaluation based on (a) 50+% of new starts stayed on therapy for 90+ days and 
(b) 5+% of new starts had discontinued therapy before 30 days. Drugs which were 
expected to generate the most savings from this policy were then identified for the 
final list for evaluating potential savings from a 15-day initial fill policy. RESULTS: 
A total of 19 unique drugs were included in the final analysis of potential savings 
from a 15-day initial fill policy. These drugs were associated with high costs per 
prescription and high discontinuation rates. Assuming savings of 15-days of therapy 
from all discontinuations, the total annual savings from these 19 drugs was esti-
mated to be $23.3 million. A conservative estimate with savings from only 50% of 
discontinuations was an annual savings of $11.6 million. CONCLUSIONS: Results 
indicate substantial savings could be achieved from a 15-day initial fill policy for 
some outpatient medications. Further consideration of such a policy must take into 
account the specific disease state and potential problems in disruption of therapy.
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OBJECTIVES: While there is ample information on the activities needed to trans-
form into a patient-centered medical home (PCMH), previous research lacks focus 
on cost as an obstacle to transformation. This is particularly important in small 
primary care practices (< 10 full-time equivalent [FTE] providers), which serve a 
large number of outpatients. Therefore, the objective of this study was to estimate 
the cost of achieving and sustaining PCMH recognition for small primary care prac-
tices. METHODS: Using semi-structured interviews, we developed a cost collection 
